Autophagy activation promotes clearance of α-synuclein inclusions in fibril-seeded human neural cells.
AMP-activated kinase (AMPK)
Lewy bodies
Parkinson disease
autophagy
neurodegeneration
neuron
p62 (sequestosome 1 (SQSTM1))
protein degradation
protein fibril
α-synuclein (α-synuclein)
Journal
The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R
Informations de publication
Date de publication:
27 09 2019
27 09 2019
Historique:
received:
03
04
2019
revised:
28
07
2019
pubmed:
4
8
2019
medline:
19
5
2020
entrez:
4
8
2019
Statut:
ppublish
Résumé
There is much interest in delineating the mechanisms by which the α-synuclein protein accumulates in brains of individuals with Parkinson's disease (PD). Preclinical studies with rodent and primate models have indicated that fibrillar forms of α-synuclein can initiate the propagation of endogenous α-synuclein pathology. However, the underlying mechanisms by which α-synuclein fibrils seed pathology remain unclear. To investigate this further, we have used exogenous fibrillar α-synuclein to seed endogenous α-synuclein pathology in human neuronal cell lines, including primary human neurons differentiated from induced pluripotent stem cells. Fluorescence microscopy and immunoblot analyses were used to monitor levels of α-synuclein and key autophagy/lysosomal proteins over time in the exogenous α-synuclein fibril-treated neurons. We observed that temporal changes in the accumulation of cytoplasmic α-synuclein inclusions were associated with changes in the key autophagy/lysosomal markers. Of note, chloroquine-mediated blockade of autophagy increased accumulation of α-synuclein inclusions, and rapamycin-induced activation of autophagy, or use of 5'-AMP-activated protein kinase (AMPK) agonists, promoted the clearance of fibril-mediated α-synuclein pathology. These results suggest a key role for autophagy in clearing fibrillar α-synuclein pathologies in human neuronal cells. We propose that our findings may help inform the development of human neural cell models for screening of potential therapeutic compounds for PD or for providing insight into the mechanisms of α-synuclein propagation. Our results further add to existing evidence that AMPK activation may be a therapeutic option for managing PD.
Identifiants
pubmed: 31375560
pii: S0021-9258(20)34985-1
doi: 10.1074/jbc.RA119.008733
pmc: PMC6768637
doi:
Substances chimiques
SQSTM1 protein, human
0
Sequestosome-1 Protein
0
alpha-Synuclein
0
Protein Kinases
EC 2.7.-
AMP-Activated Protein Kinase Kinases
EC 2.7.11.3
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
14241-14256Informations de copyright
© 2019 Gao et al.
Références
Neurobiol Aging. 2003 Mar-Apr;24(2):197-211
pubmed: 12498954
J Biol Chem. 2003 Jul 4;278(27):25009-13
pubmed: 12719433
Int J Biochem Cell Biol. 2004 Dec;36(12):2551-62
pubmed: 15325592
Science. 2004 Aug 27;305(5688):1292-5
pubmed: 15333840
Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):145-50
pubmed: 18162536
Acta Neuropathol. 2008 Apr;115(4):409-15
pubmed: 18231798
Int J Biochem Cell Biol. 2008;40(9):1835-49
pubmed: 18291704
Nat Med. 2008 May;14(5):504-6
pubmed: 18391962
Nat Med. 2008 May;14(5):501-3
pubmed: 18391963
J Biol Chem. 2008 Aug 29;283(35):23542-56
pubmed: 18566453
Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):13010-5
pubmed: 19651612
PLoS One. 2010 Feb 19;5(2):e9313
pubmed: 20174468
J Biol Chem. 2010 Apr 30;285(18):13621-9
pubmed: 20200163
Arch Neurol. 2010 Dec;67(12):1464-72
pubmed: 20697033
J Biol Chem. 2010 Nov 5;285(45):34885-98
pubmed: 20805224
J Cell Biol. 2010 Sep 20;190(6):1023-37
pubmed: 20855506
Neuron. 2011 Oct 6;72(1):57-71
pubmed: 21982369
Mol Cell Biol. 2012 Jan;32(1):2-11
pubmed: 22025673
Mol Neurodegener. 2012 Aug 14;7:38
pubmed: 22892036
Science. 2012 Nov 16;338(6109):949-53
pubmed: 23161999
Neurobiol Aging. 2013 May;34(5):1504-15
pubmed: 23200460
Mov Disord. 2013 Jan;28(1):31-40
pubmed: 23390095
J Biol Chem. 2013 May 24;288(21):15194-210
pubmed: 23532841
Exp Mol Med. 2013 May 10;45:e22
pubmed: 23661100
Neurobiol Dis. 2014 Mar;63:1-11
pubmed: 24269733
Mol Biol Cell. 2014 Dec 15;25(25):4010-23
pubmed: 25298402
Autophagy. 2014;10(12):2171-92
pubmed: 25484190
Mov Disord. 2015 Oct;30(12):1639-47
pubmed: 25594542
Autophagy. 2015;11(9):1443-57
pubmed: 26207393
Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):1931-6
pubmed: 26839413
J Biol Chem. 2016 Sep 2;291(36):18675-88
pubmed: 27382062
J Neurochem. 2017 Feb;140(4):662-678
pubmed: 27424880
Science. 2016 Sep 30;353(6307):
pubmed: 27708076
Acta Neuropathol. 2017 Feb;133(2):303-319
pubmed: 27888296
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):1183-1188
pubmed: 28096359
Mol Neurobiol. 2018 Mar;55(3):1847-1860
pubmed: 28229331
Cell. 2017 Mar 9;168(6):960-976
pubmed: 28283069
Acta Neuropathol. 2017 Oct;134(4):629-653
pubmed: 28527044
J Biol Chem. 2017 Aug 11;292(32):13482-13497
pubmed: 28611062
Proc Natl Acad Sci U S A. 2017 Sep 26;114(39):E8284-E8293
pubmed: 28900002
Front Mol Neurosci. 2017 Sep 27;10:311
pubmed: 29021741
Mol Neurodegener. 2017 Nov 3;12(1):80
pubmed: 29100525
Autophagy. 2018;14(1):98-119
pubmed: 29198173
J Parkinsons Dis. 2018;8(2):303-322
pubmed: 29400668
Cell Tissue Res. 2018 Jul;373(1):161-173
pubmed: 29480459
Curr Med Chem. 2019;26(20):3702-3718
pubmed: 29484979
Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):E2634-E2643
pubmed: 29487216
Acta Neuropathol. 2018 Jun;135(6):855-875
pubmed: 29502200
J Parkinsons Dis. 2018;8(2):161-181
pubmed: 29614701
Front Neurosci. 2018 May 23;12:344
pubmed: 29875627
Aging Dis. 2018 Apr 1;9(2):273-286
pubmed: 29896416
Cell Death Dis. 2018 Jul 9;9(7):757
pubmed: 29988147
Acta Neuropathol Commun. 2018 Aug 14;6(1):79
pubmed: 30107856
Lancet Neurol. 2018 Sep;17(9):802-815
pubmed: 30129476
Expert Opin Ther Targets. 2018 Oct;22(10):823-832
pubmed: 30185079
Neurobiol Dis. 2018 Dec;120:76-87
pubmed: 30194047